Video

Dr. Dandoy on Overcoming Challenges with TA-TMA

Christopher E. Dandoy, MD, MSc, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy. The primary challenges are diagnosing and identifying TA-TMA in patients.

Christopher E. Dandoy, MD, MSc, a professor at Cincinnati Children’s Hospital, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy (TA-TMA). The primary challenges are diagnosing and identifying TA-TMA in patients.

Dandoy recommends screening for TA-TMA to overcome this issue. Institutions should obtain complete blood counts for the first month in patients following transplant, as well as renal profiles to look at kidney injury on a daily basis. In addition, physicians should look at lactate dehydrogenase, urine, and for signs of schistocytes in the blood. Dandoy concludes they should also monitor blood pressure closely.

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD